Following today’s announcements from the MHRA and NICE about a new drug, lecanemab – which approve its use in Great Britain, but block its adoption in NHS England – our CEO and Founder, Prof Craig Ritchie, said the following:

“Today’s announcements mark an important step forward in the ongoing effort to deliver better treatments for Alzheimer’s disease, but they will no doubt leave patients and their families with uncertainty about what it means for them.